Ticker LaunchReverse merger · Completed · NBSE
NeuBase Therapeutics, Inc.
Reverse merger with Ohr Pharmaceutical, Inc. (OHRP)
NeuBase Therapeutics, Inc. merged into Ohr Pharmaceutical, Inc. (OHRP), a Nasdaq-listed clinical-stage biotech, in a reverse merger that takes the private company public. The deal was announced on Jan 3, 2019 and closed on Jul 12, 2019. The combined company trades as NeuBase Therapeutics, Inc. (NBSE) on Nasdaq.
NeuBase Therapeutics develops therapies for genetic diseases using a peptide-nucleic acid antisense oligonucleotide (PATrOL) platform, with initial indications in Huntington's disease and myotonic dystrophy that can be delivered systemically.
- Status
- Completed
- Private company
- NeuBase Therapeutics, Inc.
- Public company
- Ohr Pharmaceutical, Inc. (OHRP)
- Public company business before
- Nasdaq-listed clinical-stage biotech
- Announced
- Jan 3, 2019
- Closed
- Jul 12, 2019
- Combined company
- NeuBase Therapeutics, Inc. (NBSE)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Concurrent financing and investors
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
Other completed reverse mergers
- Stabilis Energy LLCinto American Electric Technologies, Inc. · Jul 26, 2019
- Patagonia Gold Plcinto Hunt Mining Corp. · Jul 22, 2019
- Salarius Pharmaceuticals, LLCinto Flex Pharma, Inc. · Jul 19, 2019
- Emmaus Life Sciences, Inc.into MYnd Analytics, Inc. · Jul 17, 2019
- Hire Quest Holdings, LLCinto Command Center, Inc. · Jul 15, 2019
- Jin Wan Hong (BVI) International Holdings Limitedinto Jin Wan Hong International Holdings Limited · Jul 15, 2019